Current Diabetes Reports

, Volume 3, Issue 3, pp 235–241 | Cite as

Prevention of type 2 diabetes

  • Samy I. McFarlane
  • John J. Shin
  • Tanja Rundek
  • J. Thomas Bigger


Diabetes is a major public health problem that is approaching epidemic proportions in our society and worldwide. Cardiovascular disease is the major cause of morbidity and mortality in people with diabetes. Control of cardiovascular disease risk factors is achieved only in a minority of patients. Given the magnitude of the problem and the seriousness of diabetes complications, prevention appears to be a logical approach to curb the rising prevalence of the disease. Interventions such as lifestyle modifications and the use of metformin and acarbose have been shown in randomized prospective trials to prevent diabetes in high-risk patients. Other interventions are currently being examined in large prospective studies. It is likely that one or a combination of these approaches will make diabetes prevention a reality in the near future.


Metformin Rosiglitazone Impaired Glucose Tolerance Valsartan Ramipril 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Donovan D Jr: Epidemiology of diabetes and its burden in the world and in the United States. In Principles of Diabetes Mellitus. Edited by Poretsky L. Boston, MA: Kluwer Academic Publishers; 2002:107–121.Google Scholar
  2. 2.
    Mokdad AH, Ford ES, Bowman BA, et al.: The continuing increase of diabetes in the US. Diabetes Care 2001, 24:412.PubMedCrossRefGoogle Scholar
  3. 3.
    United States Department of Health and Human Services: Healthy People 2010. Washington, DC: United States Department of Health and Human Services; 2000.Google Scholar
  4. 4.
    Rosenbloom AL, Joe JR, Young RS, Winter WE: Emerging epidemic of type 2 diabetes in youth. Diabetes Care 1999, 22:345–354.PubMedCrossRefGoogle Scholar
  5. 5.
    Type 2 diabetes in children and adolescents. American Diabetes Association [no authors listed]. Diabetes Care 2000, 23:381–389.Google Scholar
  6. 6.
    McFarlane SI, Banerji M, Sowers JR: Insulin resistance and cardiovascular disease. J Clin Endocrinol Metab 2001, 86:713–718. An excellent review of the current literature and present knowledge regarding insulin resistance and CVD. This review has been frequently cited. It comprehensively covers the most important evidence on the association between hyperinsulinemia and coronary artery disease from large prospective studies. It also emphasizes the possible preventive strategies.PubMedCrossRefGoogle Scholar
  7. 7.
    Kothari V, Stevens RJ, Adler AI, et al.: Risk of stroke in type 2 diabetes estimated by the UK Prospective Diabetes Study Risk Engine. UK Prospective Diabetes Study Group UKPDS 60. Stroke 2002, 33:1776–1781.PubMedCrossRefGoogle Scholar
  8. 8.
    Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group [no authors listed]. BMJ 1998, 317:703–713.Google Scholar
  9. 9.
    Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group [no authors listed]. Lancet 1998, 352:837–853.Google Scholar
  10. 10.
    Rundek T, Elkind MS, Pittman J, et al.: Carotid intima-media thickness is associated with allelic variants of stromelysin-1, interleukin-6, and hepatic lipase genes: the Northern Manhattan Prospective Cohort Study. Stroke 2002, 33:1420–1423.PubMedCrossRefGoogle Scholar
  11. 11.
    Hansson L, Zanchetti A, Carruthers SG, et al.: Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998, 351:1755–1762.PubMedCrossRefGoogle Scholar
  12. 12.
    McFarlane SI, Jacober SJ, Winer N, et al.: Control of cardiovascular risk factors in patients with diabetes and hypertension at urban academic medical centers. Diabetes Care 2002, 25:718–723. Showed that optimal control of CVD risk factors in adults with diabetes was achieved only in a minority of patients at two major urban medical centers in Brooklyn, NY, and Detroit, MI. Among 1372 patients, only 3.2% met the combined ADA goal for BP, LDL cholesterol, and hemoglobin A1c. The authors provide an excellent discussion on the inherent difficulties in achieving the complex ADA guidelines in the present health care systems.PubMedCrossRefGoogle Scholar
  13. 13.
    McFarlane SI, Shin JH, Joseph L, et al.: Blood pressure control in patients with diabetes mellitus at different institutions [abstract]. Am J Hypertens 2002, 15:9A.CrossRefGoogle Scholar
  14. 14.
    Burt VL, Whelton P, Roccella EJ, et al.: Prevalence of hypertension in the US adult population. Results from the Third National Health and Nutrition Examination Survey, 1988–1991. Hypertension 1995, 25:305–313.PubMedGoogle Scholar
  15. 15.
    American Diabetes Association: Diabetes 2001 Vital Statistics. Alexandria, VA: American Diabetes Association; 2001.Google Scholar
  16. 16.
    Harris MI, Flegal KM, Cowie CC, et al.: Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults. The Third National Health and Nutrition Examination Survey, 1988–1994. Diabetes Care 1998, 21:518–524.PubMedCrossRefGoogle Scholar
  17. 17.
    Haffner SM: Epidemiology of type 2 diabetes: risk factors. Diabetes Care 1998, 21(suppl 3):C3-C6.PubMedGoogle Scholar
  18. 18.
    Burrows NR, Geiss LS, Engelgau MM, Acton KJ: Prevalence of diabetes among Native Americans and Alaska Natives, 1990–1997: an increasing burden. Diabetes Care 2000, 23:1786–1790.PubMedCrossRefGoogle Scholar
  19. 19.
    Sowers JR, Epstein M, Frohlich ED: Diabetes, hypertension, and cardiovascular disease: an update. Hypertension 2001, 37:1053–1059.PubMedGoogle Scholar
  20. 20.
    McFarlane S, Farag A, Sowers J: Hypertension. In Principles of Diabetes Mellitus. Edited by Poretsky L. Boston, MA: Kluwer Academic Publishers; 2002:671–683.Google Scholar
  21. 21.
    Kotchen TA, Zhang HY, Covelli M, Blehschmidt N: Insulin resistance and blood pressure in Dahl rats and in one-kidney, oneclip hypertensive rats. Am J Physiol 1991, 261:E692-E697.PubMedGoogle Scholar
  22. 22.
    Sechi LA, Melis A, Tedde R: Insulin hypersecretion: a distinctive feature between essential and secondary hypertension. Metabolism 1992, 41:1261–1266.PubMedCrossRefGoogle Scholar
  23. 23.
    Beatty OL, Harper R, Sheridan B, et al.: Insulin resistance in offspring of hypertensive parents. BMJ 1993, 307:92–96.PubMedCrossRefGoogle Scholar
  24. 24.
    de Vegt F, Dekker JM, Jager A, et al.: Relation of impaired fasting and postload glucose with incident type 2 diabetes in a Dutch population: the Hoorn Study. JAMA 2001, 285:2109–2113.PubMedCrossRefGoogle Scholar
  25. 25.
    Shaw JE, Zimmet PZ, de Courten M, et al.: Impaired fasting glucose or impaired glucose tolerance. What best predicts future diabetes in Mauritius? Diabetes Care 1999, 22:399–402.PubMedCrossRefGoogle Scholar
  26. 26.
    The prevention or delay of type 2 diabetes [no authors listed]. Diabetes Care 2002, 25:742–749.Google Scholar
  27. 27.
    Gerstein HC: Fasting versus postload glucose levels: why the controversy? Diabetes Care 2001, 24:1855–1857.PubMedCrossRefGoogle Scholar
  28. 28.
    Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus [no authors listed]. Diabetes Care 1997, 20:1183–1197.Google Scholar
  29. 29.
    Gabir MM, Hanson RL, Dabelea D, et al.: The 1997 American Diabetes Association and 1999 World Health Organization criteria for hyperglycemia in the diagnosis and prediction of diabetes. Diabetes Care 2000, 23:1108–1112.PubMedCrossRefGoogle Scholar
  30. 30.
    Gabir MM, Hanson RL, Dabelea D, et al.: Plasma glucose and prediction of microvascular disease and mortality: evaluation of 1997 American Diabetes Association and 1999 World Health Organization criteria for diagnosis of diabetes. Diabetes Care 2000, 23:1113–1118.PubMedCrossRefGoogle Scholar
  31. 31.
    Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. The DECODE study group. European Diabetes Epidemiology Group. Diabetes Epidemiology: collaborative analysis of diagnostic criteria in Europe [no authors listed]. Lancet 1999, 354:617–621.Google Scholar
  32. 32.
    Davies M: New diagnostic criteria for diabetes—are they doing what they should? Lancet 1999, 354:610–611.PubMedCrossRefGoogle Scholar
  33. 33.
    Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria [no authors listed]. Arch Intern Med 2001, 161:397–405.Google Scholar
  34. 34.
    Barzilay JI, Spiekerman CF, Wahl PW, et al.: Cardiovascular disease in older adults with glucose disorders: comparison of American Diabetes Association criteria for diabetes mellitus with WHO criteria. Lancet 1999, 354:622–625.PubMedCrossRefGoogle Scholar
  35. 35.
    Tuomilehto J, Lindstrom J, Eriksson JG, et al.: Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001, 344:1343–1350. This is an important interventional study in which 522 middle-aged, overweight subjects with IGT were randomly assigned to either the intervention group (receiving counseling, diet, and physical activity) or the control group, with the mean duration of follow-up of 3.2 years. This report provides evidence that type 2 diabetes can be prevented or delayed by changes in the lifestyle of the high-risk subjects.PubMedCrossRefGoogle Scholar
  36. 36.
    Knowler WC, Barrett-Connor E, Fowler SE, et al.: Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002, 346:393–403. The DPP, an important 3-year interventional study, showed that intensive lifestyle interventions or treatment with metformin plus standard lifestyle recommendations is effective in preventing or delaying the onset of type 2 diabetes in overweight prediabetic persons. The study also showed that lifestyle interventions are more effective, with lower number needed to treat, in the prevention of diabetes than metformin.PubMedCrossRefGoogle Scholar
  37. 37.
    Pan XR, Li GW, Hu YH, et al.: Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care 1997, 20:537–544.PubMedCrossRefGoogle Scholar
  38. 38.
    Chiasson JL, Josse RG, Gomis R, et al.: Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 2002, 359:2072–2077.PubMedCrossRefGoogle Scholar
  39. 39.
    Buchanan TA, Xiang AH, Peters RK, et al.: Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in highrisk Hispanic women. Diabetes 2002, 51:2796–2803.PubMedCrossRefGoogle Scholar
  40. 40.
    Hansson L, Lindholm LH, Niskanen L, et al.: Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomized trial. Lancet 1999, 353:611–616.PubMedCrossRefGoogle Scholar
  41. 41.
    Gerstein HC: Reduction of cardiovascular events and microvascular complications in diabetes with ACE inhibitor treatment: HOPE and MICRO-HOPE. Diabetes Metab Res Rev 2002, 18(suppl 3):S82-S85. Discusses the HOPE study, an international randomized trial, designed to evaluate the effects of the ACE inhibitor ramipril and vitamin E in 9541 patients at high risk for cardiovascular events. Ramipril use was associated with a significant 25% reduction in risk for the vascular events after a median follow-up period of 4.5 years. It also highlights the MICRO-HOPE substudy, in which ramipril treatment was associated with a decreased risk of development of overt nephropathy. An interesting finding in the HOPE study was that ramipril treatment was associated with a significant 34% reduction in new diagnoses of diabetes.PubMedCrossRefGoogle Scholar
  42. 42.
    Yusuf S, Sleight P, Pogue J, et al.: Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000, 342:145–153.PubMedCrossRefGoogle Scholar
  43. 43.
    Lindholm LH, Ibsen H, Dahlof B, et al.: Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet 2002, 359:1004–1010. The LIFE trial was a large randomized trial that provided important evidence for use of ARBs. Among 1195 diabetic patients, a substantial reduction in total and cardiovascular mortality favoring losartan was found. This report provided an additional and interesting observation that new-onset diabetes developed 25% less frequently in the losartan-treated group.PubMedCrossRefGoogle Scholar
  44. 44.
    Nateglinide and valsartan in impaired glucose tolerance outcome research: rationale and design of the NAVIGATOR trial. The NAVIGATOR Trial Steering Committee [no authors listed] [abstract]. Diabetes 2002, 51:A116.Google Scholar
  45. 45.
    The Diabetes Prevention Program. Design and methods for a clinical trial in the prevention of type 2 diabetes [no authors listed]. Diabetes Care 1999, 22:623–634.Google Scholar
  46. 46.
    Henriksson J: Effects of physical training on the metabolism of skeletal muscle. Diabetes Care 1992, 15:1701–1711.PubMedCrossRefGoogle Scholar
  47. 47.
    Devlin JT: Effects of exercise on insulin sensitivity in humans. Diabetes Care 1992, 15:1690–1693.PubMedCrossRefGoogle Scholar
  48. 48.
    Helmrich SP, Ragland DR, Leung RW, Paffenbarger RS Jr: Physical activity and reduced occurrence of non-insulin-dependent diabetes mellitus. N Engl J Med 1991, 325:147–152.PubMedCrossRefGoogle Scholar
  49. 49.
    Eriksson KF, Lindgarde F: Prevention of type 2 (non-insulin-dependent) diabetes mellitus by diet and physical exercise. The 6-year Malmo feasibility study. Diabetologia 1991, 34:891–898.PubMedCrossRefGoogle Scholar
  50. 50.
    Bjorntorp P: Abdominal obesity and the development of non-insulin-dependent diabetes mellitus. Diabetes Metab Rev 1988, 4:615–622.PubMedCrossRefGoogle Scholar
  51. 51.
    Wing RR, Venditti E, Jakicic JM, et al.: Lifestyle intervention in overweight individuals with a family history of diabetes. Diabetes Care 1998, 21:350–359.PubMedCrossRefGoogle Scholar
  52. 52.
    Long SD, O'Brien K, MacDonald KG Jr, et al.: Weight loss in severely obese subjects prevents the progression of impaired glucose tolerance to type II diabetes. A longitudinal interventional study. Diabetes Care 1994, 17:372–375.PubMedCrossRefGoogle Scholar
  53. 53.
    Lillioja S, Mott DM, Howard BV, et al.: Impaired glucose tolerance as a disorder of insulin action. Longitudinal and cross-sectional studies in Pima Indians. N Engl J Med 1988, 318:1217–1225.PubMedCrossRefGoogle Scholar
  54. 54.
    Feskens EJ, Virtanen SM, Rasanen L, et al.: Dietary factors determining diabetes and impaired glucose tolerance. A 20-year follow-up of the Finnish and Dutch cohorts of the Seven Countries Study. Diabetes Care 1995, 18:1104–1112.PubMedCrossRefGoogle Scholar
  55. 55.
    Marshall JA, Hoag S, Shetterly S, Hamman RF: Dietary fat predicts conversion from impaired glucose tolerance to NIDDM. The San Luis Valley Diabetes Study. Diabetes Care 1994, 17:50–56.PubMedCrossRefGoogle Scholar
  56. 56.
    Swinburn BA, Metcalf PA, Ley SJ: Long-term (5-year) effects of a reduced-fat diet intervention in individuals with glucose intolerance. Diabetes Care 2001, 24:619–624.PubMedCrossRefGoogle Scholar
  57. 57.
    McGarry JD, Dobbins RL: Fatty acids, lipotoxicity and insulin secretion. Diabetologia 1999, 42:128–138.PubMedCrossRefGoogle Scholar
  58. 58.
    Kirpichnikov D, McFarlane SI, Sowers JR: Metformin: an update. Ann Intern Med 2002, 137:25–33.PubMedGoogle Scholar
  59. 59.
    Fontbonne A, Charles MA, Juhan-Vague I, et al.: The effect of metformin on the metabolic abnormalities associated with upper-body fat distribution. BIGPRO Study Group. Diabetes Care 1996, 19:920–926.PubMedCrossRefGoogle Scholar
  60. 60.
    Stumvoll M, Haring HU: Glitazones: clinical effects and molecular mechanisms. Ann Med 2002, 34:217–224.PubMedGoogle Scholar
  61. 61.
    Delgado H, Lehmann T, Bobbioni-Harsch E, et al.: Acarbose improves indirectly both insulin resistance and secretion in obese type 2 diabetic patients. Diabetes Metab 2002, 28:195–200.PubMedGoogle Scholar
  62. 62.
    Saloranta C, Guitard C, Pecher E, et al.: Nateglinide improves early insulin secretion and controls postprandial glucose excursions in a prediabetic population. Diabetes Care 2002, 25:2141–2146.PubMedCrossRefGoogle Scholar
  63. 63.
    Sharma AM, Janke J, Gorzelniak K, et al.: Angiotensin blockade prevents type 2 diabetes by formation of fat cells. Hypertension 2002, 40:609–611.PubMedCrossRefGoogle Scholar
  64. 64.
    Freeman DJ, Norrie J, Sattar N, et al.: Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation 2001, 103:357–362.PubMedGoogle Scholar
  65. 65.
    McFarlane SI, Muniyappa R, Francisco R, Sowers JR: Clinical review 145: Pleiotropic effects of statins: lipid reduction and beyond. J Clin Endocrinol Metab 2002, 87:1451–1458. Rated one of the most frequently read articles by the Journal of Clinical Endocrinology and Metabolism, this clinical review bridges the basic and clinical science on the effects of statins and their roles beyond traditional thinking of the lipid-lowering effect. The effect of statins on inflammation and nitric oxide in the vasculature, kidney, and bone were also discussed. Potential beneficial pleiotropic effects of statins were comprehensively reviewed in this article.PubMedCrossRefGoogle Scholar

Copyright information

© Current Science Inc 2003

Authors and Affiliations

  • Samy I. McFarlane
    • 1
  • John J. Shin
  • Tanja Rundek
  • J. Thomas Bigger
  1. 1.Division of Endocrinology, Diabetes and HypertensionSUNY-Down-state Health Science Center at Brooklyn/Kings County Hospital CenterBrooklynUSA

Personalised recommendations